Home›Rheumatology› Protocol targets host-response biomarker accuracy for PJI in inflammatory arthritis
Protocol targets host-response biomarker accuracy for PJI in inflammatory arthritisNew plan to improve testing for joint infection in arthritis
Frontiers in MedicinePublished October 28, 2026Study authors: Jixin Chen, Qinxin Zhou, Yongming Zhang, Jianliang Chen, Xiaodong Zheng, Feng YeDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Recognize this as a protocol only; no diagnostic accuracy data are yet available.
This publication is a protocol for a systematic review and diagnostic test accuracy meta-analysis. It does not report any analyzed data. The planned review will evaluate the diagnostic performance and reported diagnostic thresholds of serum, plasma, whole-blood, and synovial host-response biomarkers for periprosthetic joint infection in adults with inflammatory arthritis.
The protocol specifies secondary analyses of threshold effects, reference-standard incorporation bias, joint type, infection chronicity, disease activity, and immunosuppressive therapy. These factors are relevant because inflammatory arthritis and its treatments may alter host-response biomarker levels and complicate the interpretation of standard diagnostic cutoffs.
The stated practice relevance is to determine whether commonly used and emerging host-response biomarkers retain adequate diagnostic performance in inflammatory arthritis, to identify candidate population-specific thresholds that require prospective external validation, and to clarify where evidence is insufficient for clinical implementation.
The only limitation reported is that the work is at the protocol stage, with no results reported. No safety data, funding information, or conflicts of interest are reported. Because no diagnostic accuracy estimates are yet available, no conclusions can be drawn about biomarker performance in this population.
How this fits prior evidence
Prior coverage has focused on prevention and treatment of periprosthetic joint infection, including defensive antibacterial coating, intraosseous vancomycin, antibiotic holiday duration, and nutritional support, as well as multimodal laboratory diagnostics for biofilm and polymicrobial bone and joint infections. This protocol addresses a related but distinct gap: whether host-response biomarkers retain diagnostic accuracy in inflammatory arthritis. It does not confirm or contrast prior findings because no results are reported. Instead, it sets up a planned synthesis that may clarify how inflammatory arthritis affects biomarker thresholds, a question not addressed by the prior prevention and treatment studies.
Living with inflammatory arthritis can make it very hard to tell if a new joint infection is starting. Because these conditions often overlap, doctors need reliable ways to tell if a patient needs different treatment for an infection or if their current arthritis management is enough.
Researchers are preparing a plan to study how well certain markers in blood, plasma, and joint fluid work as diagnostic tools. These markers are signs of the body's immune response. The goal is to see if these tests can accurately identify infections in people with inflammatory arthritis.
It is important to note that this is currently a protocol, which means the study is in the planning stages. No data has been analyzed yet, and no results are available. The final goal is to find specific thresholds for these tests to help doctors make clearer decisions for their patients.
What this means for you:
A new plan is being organized to improve how doctors detect joint infections in people with arthritis.
Common questions
How will this help people with arthritis?
This research plan aims to help doctors better identify joint infections. Because infections and inflammatory arthritis can look similar, finding reliable markers in blood or joint fluid can help doctors provide more accurate care for patients with these conditions.
Are there any results from this study yet?
No results have been reported yet. This is currently a protocol, which means the researchers are still in the planning stage and have not yet analyzed any data or outcomes.
Periprosthetic joint infection (PJI) can sometimes be difficult to diagnose in patients with inflammatory arthritis because autoimmune disease activity and immunomodulatory treatment can alter systemic and synovial inflammatory responses. Diagnostic thresholds derived predominantly from patients with osteoarthritis may therefore produce false-positive or false-negative classifications in this population. Recent rheumatoid arthritis-specific cohorts and studies of synovial host-response biomarkers have expanded the evidence base beyond that available in earlier reviews.
We will conduct a systematic review and diagnostic test accuracy meta-analysis of studies evaluating serum, plasma, whole-blood, or synovial host-response biomarkers for hip or knee PJI in adults with inflammatory arthritis. We will search MEDLINE, Embase, Web of Science, Scopus, CINAHL, the Cochrane Library, CNKI, Wanfang, VIP, and SinoMed from inception without language restrictions. Two reviewers will independently screen records, extract data, and assess risk of bias and applicability using QUADAS-3; an adapted QUADAS-C assessment will additionally be used for direct comparative accuracy studies. For each biomarker and clinically coherent threshold group, paired sensitivity and specificity will be synthesized using bivariate random-effects models or hierarchical summary receiver operating characteristic models. Threshold effects, reference-standard incorporation bias, joint type, infection chronicity, disease activity, and immunosuppressive therapy will be examined through subgroup, meta-regression, and sensitivity analyses when data permit. Certainty of evidence will be assessed using GRADE for diagnostic tests.
This review aims to determine whether commonly used and emerging host-response biomarkers retain adequate diagnostic performance in inflammatory arthritis, identify candidate population-specific thresholds that require prospective external validation, and clarify where evidence is insufficient for clinical implementation.
